Avacincaptad Pegol
Avacincaptad pegol is an ophthalmological medication used to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It is an RNA aptamer that inhibits complement protein C5, preventing the formation of the membrane attack complex (MAC) that damages retinal cells. This medication is administered as an intravitreal injection.
Avacincaptad pegol is an eye injection medication that inhibits complement C5 to slow vision loss in geographic atrophy secondary to AMD.
Key facts at a glance
- ATC
- S01XA32
- RxNorm
- 2645108
- Generic
- Avacincaptad Pegol
- Class
- atc-s01
- Brands
- Izervay
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 2mg
- Maximum
- consult physician
- Frequency
- monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 2mg
- Maximum
- consult physician
- Frequency
- monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid unless benefits outweigh risks
use only if potential benefit justifies potential risk to the fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid unless benefits outweigh risks
use only if potential benefit justifies potential risk to the fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid unless benefits outweigh risks
use only if potential benefit justifies potential risk to the fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
unknown if drug is excreted in human milk; weigh benefits against risks
monitor infant for adverse effects
pediatric_age
children under 18not established
not indicated for pediatric use; safety and efficacy not established
not applicable
geriatric
elderly over 65no adjustment needed
no dose adjustment required; monitor for adverse effects
routine ophthalmologic monitoring
renal_impairment
mild to moderateno adjustment needed
no dose adjustment required due to minimal systemic absorption
routine monitoring
renal_impairment
severeno adjustment needed
no dose adjustment required due to minimal systemic absorption
routine monitoring
hepatic_impairment
mild to moderateno adjustment needed
no dose adjustment required due to minimal systemic absorption
routine monitoring
hepatic_impairment
severeuse with caution
use with caution; no formal studies in severe hepatic impairment
enhanced monitoring of liver function
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
Izervay approved for geographic atrophy secondary to AMD
Drug class
Mechanism of action classification
Common uses
Therapeutic indication
Administration route
Method of administration
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Avacincaptad pegol is a PEGylated RNA aptamer that binds to and inhibits complement protein C5. By preventing C5 cleavage to C5a and C5b, it decreases membrane attack complex (MAC) formation, thereby reducing retinal cell damage.
Administered as an intravitreal injection by a healthcare professional. Potential side effects include conjunctival hemorrhage, endophthalmitis, and increased intraocular pressure. Regular eye examinations are recommended during treatment.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy